Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Final PROpel data confirm OS advantage with abiraterone plus olaparib

Final PROpel data confirm OS advantage with abiraterone plus olaparib

01 Mar 2023 bởiJairia Dela Cruz

The combination of olaparib plus abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) appears to show a consistent trend toward overall survival (OS) benefit, according to the results of the final prespecified analysis of the phase III PROpel study presented at ASCO GU 2023.

01 Mar 2023